Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1982 Mar;45(3):261–263. doi: 10.1136/jnnp.45.3.261

The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy.

A Neophytides, A N Lieberman, M Goldstein, G Gopinathan, M Leibowitz, J Bock, R Walker
PMCID: PMC491349  PMID: 7086448

Abstract

Seven patients with progressive supranuclear palsy were treated with lisuride. Mean age was 62 years (range, 52 to 68 years), and duration of disease was 4.4 years (range, 1 to 7 years). All seven had been treated with levodopa/carbidopa and three with bromocriptine; four had, at one time, shown a partial response to levodopa. One patient had also shown a partial response to bromocriptine. Lisuride was used alone in four patients, and combined with levodopa/carbidopa in three patients. Mean dose of lisuride was 2.5 mg (range, 1.5 to 5.0 mg). Mean duration of treatment was 4 months (range, 1 to 10 months). While two patients showed a reduction in rigidity, one in tremor and two in bradykinesia, in only one of them was there an overall improvement. It is postulated that the relative lack of response to lisuride may be due to a loss of both the dopaminergic and serotonergic receptors in progressive supranuclear palsy.

Full text

PDF
261

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Calne D. B., Plotkin C., Williams A. C., Nutt J. G., Neophytides A., Teychenne P. F. Long-term treatment of parkinsonism with bromocriptine. Lancet. 1978 Apr 8;1(8067):735–738. doi: 10.1016/s0140-6736(78)90856-5. [DOI] [PubMed] [Google Scholar]
  2. Corin M. S., Elizan T. S., Bender M. B. Oculomotor function in patients with Parkinson's disease. J Neurol Sci. 1972 Mar;15(3):251–265. doi: 10.1016/0022-510x(72)90068-8. [DOI] [PubMed] [Google Scholar]
  3. De Renzi E., Vignolo L. A. L-dopa for progressive supranuclear palsy. Lancet. 1969 Dec 20;2(7634):1360–1360. [PubMed] [Google Scholar]
  4. Dehaene I., Bogaerts M. L-dopa in progressive supranuclear palsy. Lancet. 1970 Aug 29;2(7670):470–470. doi: 10.1016/s0140-6736(70)90089-9. [DOI] [PubMed] [Google Scholar]
  5. Gopinathan G., Teräväinen H., Dambrosia J. M., Ward C. D., Sanes J. N., Stuart W. K., Evarts E. V., Calne D. B. Lisuride in parkinsonism. Neurology. 1981 Apr;31(4):371–376. doi: 10.1212/wnl.31.4.371. [DOI] [PubMed] [Google Scholar]
  6. Gross M. L-dopa for progressive supranuclear palsy. Lancet. 1969 Dec 20;2(7634):1359–1360. [PubMed] [Google Scholar]
  7. Horowski R. Differences in the dopaminergic effects of the ergot derivatives bromocriptine, lisuride and d-LSD as compared with apomorphine. Eur J Pharmacol. 1978 Sep 15;51(2):157–166. doi: 10.1016/0014-2999(78)90340-0. [DOI] [PubMed] [Google Scholar]
  8. Jenkins R. L-dopa for progressive supranuclear palsy. Lancet. 1969 Oct 4;2(7623):742–742. doi: 10.1016/s0140-6736(69)90449-8. [DOI] [PubMed] [Google Scholar]
  9. Klawans H. L., Jr, Ringel S. P. Observations on the efficacy of L-dopa in progressive supranuclear palsy. Eur Neurol. 1971;5(2):115–129. doi: 10.1159/000114065. [DOI] [PubMed] [Google Scholar]
  10. Lees A. J., Bannister R. The use of lisuride in the treatment of multiple system atrophy with autonomic failure (Shy-Drager syndrome). J Neurol Neurosurg Psychiatry. 1981 Apr;44(4):347–351. doi: 10.1136/jnnp.44.4.347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lieberman A. N., Kupersmith M., Gopinathan G., Estey E., Goodgold A., Goldstein M. Bromocriptine in Parkinson disease: further studies. Neurology. 1979 Mar;29(3):363–369. doi: 10.1212/wnl.29.3.363. [DOI] [PubMed] [Google Scholar]
  12. Maclean N. Sex chromatin in testicular teratomas. Lancet. 1969 Aug 30;2(7618):494–494. doi: 10.1016/s0140-6736(69)90197-4. [DOI] [PubMed] [Google Scholar]
  13. Marsden C. D., Parkes J. D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet. 1977 Feb 12;1(8007):345–349. doi: 10.1016/s0140-6736(77)91146-1. [DOI] [PubMed] [Google Scholar]
  14. Mendell J. R., Engel W. K., Chase T. N. Modification by L-dopa of a case of progressive supranuclear palsy. With evidence of defective cerebral dopamine metabolism. Lancet. 1970 Mar 21;1(7647):593–594. doi: 10.1016/s0140-6736(70)91629-6. [DOI] [PubMed] [Google Scholar]
  15. Parkes J. D., Schachter M., Marsden C. D., Smith B., Wilson A. Lisuride in parkinsonism. Ann Neurol. 1981 Jan;9(1):48–52. doi: 10.1002/ana.410090109. [DOI] [PubMed] [Google Scholar]
  16. STEELE J. C., RICHARDSON J. C., OLSZEWSKI J. PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA. Arch Neurol. 1964 Apr;10:333–359. doi: 10.1001/archneur.1964.00460160003001. [DOI] [PubMed] [Google Scholar]
  17. Sacks O. W. L-dopa for progressive suparanulcear palsy. Lancet. 1969 Sep 13;2(7620):591–592. doi: 10.1016/s0140-6736(69)90284-0. [DOI] [PubMed] [Google Scholar]
  18. Wagshul A., Daroff R. B. L-dopa for progressive supranuclear palsy. Lancet. 1969 Jul 12;2(7611):105–106. doi: 10.1016/s0140-6736(69)92413-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES